A chronic kidney disease (CKD) diagnosis raises a lot of questions at once: how did this happen, how fast will it progress, and what, realistically, can be done about it. This page explains what CKD is, how it’s diagnosed and managed under standard medical care in Malaysia, and what current stem cell research can and cannot currently show for kidney function, so you can have an informed conversation before requesting an assessment.
Symptoms and Diagnosis of Chronic Kidney Disease
Chronic kidney disease often develops silently. Many patients only discover reduced kidney function through a routine blood test, long before symptoms become noticeable, which is part of why CKD is sometimes called a “silent” condition in its earlier stages.
| Stage | Typical Presentation |
| Early CKD (Stage 1–2) | Usually no symptoms; detected through blood or urine tests |
| Moderate CKD (Stage 3) | Fatigue, mild swelling, changes in urination frequency |
| Advanced CKD (Stage 4–5) | Marked fatigue, swelling in legs/ankles, nausea, poor appetite, itching, breathlessness |
Diagnosis in Malaysia typically involves:
- Blood tests measuring estimated glomerular filtration rate (eGFR) and serum creatinine
- Urine tests checking for protein (albuminuria), a key marker of kidney damage
- Imaging, such as renal ultrasound, to assess kidney structure
- Blood pressure monitoring, since hypertension is both a cause and consequence of CKD
- Identifying underlying cause, most commonly diabetes, hypertension, or glomerular disease in the Malaysian population
CKD is staged from 1 (mild) to 5 (kidney failure, often requiring dialysis or transplant), based primarily on eGFR and the degree of protein in the urine.
Standard Care for CKD
Nephrology-led management remains the foundation of CKD care, and it focuses on slowing progression, managing complications, and protecting remaining kidney function for as long as possible.
| Approach | Purpose |
| Blood pressure control (ACE inhibitors/ARBs) | Reduces strain on the kidneys, slows progression |
| Blood sugar management | Critical for diabetic kidney disease, the leading cause of CKD in Malaysia |
| Dietary modification | Protein, sodium, potassium, and phosphate adjustments depending on stage |
| Medication review | Avoiding nephrotoxic drugs, adjusting doses for reduced kidney function |
| SGLT2 inhibitors | Increasingly used to slow CKD progression in eligible patients |
| Treating complications | Anaemia, bone mineral disorders, and fluid overload as they arise |
| Dialysis or transplant | For advanced CKD (Stage 5) when kidney function can no longer sustain the body |
This standard pathway, delivered through a nephrologist, remains the evidence-based foundation of CKD management, and nothing on this page is intended to replace it.
What Current Research Can and Cannot Show about Chronic Kidney Disease
Mesenchymal stem cell (MSC) research in kidney disease is an active and genuinely evolving area of regenerative medicine. It’s important to be precise about what this research has, and has not, established so far.
What early and preclinical research suggests:
- MSCs may help modulate inflammation and support a healthier tissue environment within the kidney in laboratory and animal models
- Some early-phase human studies have explored safety and tolerability of MSC administration in patients with reduced kidney function
- Paracrine signalling (growth factors and other molecules released by MSCs) is the mechanism most researchers believe may be relevant, rather than cells directly replacing damaged kidney tissue
What current evidence does not establish:
- No regulatory authority has approved stem cell therapy as a treatment that reverses CKD or restores lost kidney function
- Stem cell therapy is not established as a way to delay or avoid the need for dialysis
- Most published human studies are small, early-phase, and focused primarily on safety rather than confirmed clinical benefit
- Long-term outcome data in CKD populations remains limited
At 23C Regen, any discussion of stem cell therapy for CKD is framed within this evidence picture. We do not position our service as a guaranteed way to avoid dialysis or reverse kidney damage. An assessment exists to review your specific situation honestly against what current evidence actually supports.
Risks and Exclusions
Any discussion of cell-based therapy should include a clear-eyed look at risk, and at who may not be suitable.
General risks associated with MSC administration can include:
- Infusion-related reactions (fever, chills, discomfort at the infusion site)
- Rare allergic or immune responses
- Uncertainty around long-term effects, given the relatively early stage of clinical evidence in CKD specifically
Patients who may be excluded from assessment or treatment can include those with:
- Active, untreated infection
- Active malignancy or recent cancer history, pending oncology clearance
- Significant uncontrolled bleeding disorders
- Pregnancy
- Advanced CKD already requiring urgent dialysis initiation, where the priority is immediate nephrology-led management
Suitability is determined individually, not assumed, which is exactly why a proper assessment, not a general consultation alone, matters before any decision is made.
Assessment Records You’ll Need for Chronic Kidney Disease
A meaningful assessment depends on having a clear picture of your current kidney function and medical history. Bringing the following helps our team give you an accurate, honest opinion rather than a generic one:
- Recent blood test results, including eGFR, creatinine, and electrolytes
- Urine test results, particularly protein/albumin levels if available
- Imaging reports, such as renal ultrasound, if performed
- A list of current medications, including any kidney-related prescriptions
- Nephrologist’s notes or referral letter, if you are already under specialist care
- Relevant history of diabetes, hypertension, or other contributing conditions
If you don’t have all of these on hand, that’s not a barrier to booking, our team can advise on what’s needed before your assessment date.
Chronic Kidney Disease Follow-Up
CKD is a progressive, long-term condition, and care doesn’t end after a single visit regardless of what pathway you choose. Our approach includes:
- A clear explanation of findings after your initial assessment
- Honest guidance on whether stem cell therapy is a reasonable option to discuss further, or whether standard nephrology care remains the appropriate path
- Coordination notes you can share with your treating nephrologist, since we view this as complementary to, not a replacement for, your existing renal care team
- Scheduled review points if you proceed with any treatment plan, to monitor how you’re responding over time
Questions to Discuss During Your Chronic Kidney Disease Assessment
Coming prepared with questions helps you get the most out of your visit:
- What stage is my CKD currently at, and what does that mean for my options?
- What does current evidence actually show for stem cell therapy at my specific stage?
- Will this replace, delay, or work alongside my current nephrology care?
- What are the realistic risks given my overall health and kidney function?
- How will progress or response be measured and monitored?
- What happens if my kidney function continues to decline despite treatment?
Frequently Asked Questions
Can stem cell therapy cure chronic kidney disease?
No. There is currently no cure for CKD, and stem cell therapy is not established as a way to reverse kidney damage or restore full kidney function.
Will this treatment help me avoid dialysis?
We cannot guarantee that. Dialysis decisions are based on kidney function and clinical need, determined by your nephrologist, not by any single treatment.
Is stem cell therapy a replacement for my current kidney medications?
No. Any assessment at 23C Regen is intended to complement, not replace, your existing nephrology-led care and prescribed medications.
How is the stem cell source determined for this condition?
Our treatments use laboratory-cultured Wharton’s Jelly-derived mesenchymal stem cells. Your doctor will explain the specific protocol considered for your case during assessment.
Do I need a referral from my nephrologist to book an assessment?
A referral isn’t required, but bringing your nephrologist’s notes and recent test results helps us give you a more accurate, informed assessment.
What happens if I’m found unsuitable for treatment?
You’ll receive an honest explanation of why, along with guidance on continuing appropriate standard care through your nephrology team.
Request a Kidney Health Assessment
If you’d like an honest, evidence-based conversation about your CKD and what current research can and cannot offer, request an assessment. Review our broader treatable conditions, learn more about stem cell therapy, or check pricing beforehand